# Clinical use of the 31-gene expression profile for informing sentinel lymph node biopsies: a prospective, multicenter study

J. Michael Guenther, MD<sup>1</sup>, Christine N. Bailey, MPH<sup>2</sup>, Kelli Ahmed, PhD<sup>2</sup>, Clare Johnson, RN<sup>2</sup>, Brian Martin, PhD<sup>2</sup>, Sarah J. Kurley, PhD<sup>2</sup>, Maki Yamamoto, MD<sup>3</sup> <sup>1</sup>St. Elizabeth Physicians, Edgewood, KY, USA, <sup>2</sup>Castle Biosciences, Friendswood, TX, USA, <sup>3</sup>University of California-Irvine, Orange, CA, USA

### Background

A positive sentinel lymph node (SLN) is an indicator of poor outcomes in cutaneous melanoma (CM); however, using clinicopathologic factors to select patients results in up to 88% of all patients having a negative SLNB.<sup>1</sup>

>SLN biopsies (SLNBs) cost up to \$15,223 and are associated with complications in 11.3% of cases.<sup>2-3</sup> In order to have a positive impact on survival, 142 SLNBs are needed to find one patient who will die from their disease.<sup>4</sup>

>The 31-gene expression profile (GEP) test stratifies patient risk for recurrence, metastasis, and melanoma death as Class 1A (low-risk), Class 1B/2A (intermediate risk), and Class 2B (high-risk).

The 31-GEP is validated to identify patients who have <5% risk of positive SLNB and good outcomes, indicating that these patients could safely forego the procedure.<sup>5-6</sup>

# **Clinical Implications**

Most patients have a negative SLNB

Identifying patients at low risk of having a positive SLNB can:


Reduce the number of unnecessary SLNBs

- Reduce SLNB-associated complications
- Reduce healthcare costs

## **Study Design**

 $\hat{}$  Patients with CM  $\hat{}$ considering SLNB

Physician and patient make decision about SLNB after receiving 31-GEP results



### Results


### Table 1. Demographic data (n=193)


		•	•	
Descriptor	Class 1A (n=138)	Class 1B (n=23)	Class 2A (n=13)	Class 2B (n=19)
<b>Age</b> , median (range)	65 (25-87)	70 (39-90)	65 (22-84)	69 (50-88)
<b>Breslow thickness</b> , median (range)	0.9 (0.2-1.9)	0.8 (0.6-1.85)	1.5 (0.9-1.9)	1.1 (0.4-2)
Ulceration				
Absent	132 (95.7%)	20 (87.0%)	7 (53.9%)	9 (47.4%)
Present	4 (2.9%)	2 (8.7%)	6 (46.2%)	10 (52.6%)
Unknown	2 (1.5%)	1 (4.4%)	0 (0%)	0 (0%)
Mitotic rate (1/mm <sup>2</sup> )				
<2	99 (78.0%)	14 (63.6%)	4 (33.3%)	10 (55.6%)
≥2	28 (22.1%)	8 (36.4%)	8 (66.7%)	8 (44.4%)
Physician Specialty				
Surgical Oncologist	125 (90.6%)	17 (73.9%)	13 (100%)	17 (89.5%)
Dermatologist	10 (7.3%)	5 (21.7%)	0 (0%)	0 (0%)
Medical Oncologist	3 (2.2%)	1 (4.4%)	0 (0%)	2 (10.5%)

Presented at the Winter Clinical 2023 Conferences.

All Pts (n=193)	P-value
65 (22-90)	0.118
0.9 (0.2-2)	<0.001
168 (87.1%) 22 (11.4%) 3 (1.6%)	<0.001
127 (70.9%) 52 (29.1%)	0.003
172 (89.1%) 15 (7.8%) 6 (3.1%)	0.037


### Results





population relative to the baseline control (59.1% vs. 78.0%). In Class 1A patients, the reduction in SLNB performance was 29.4%. \*\* p<0.01

### Table 2. Factors associated with decision to perform or forego SLNB.



Stepwise selection on logistic regression model to identify factors associated with performing an SLNB. \*pvalues <0.01; Other variables, while contributing to the model, did not reach the statistical significance mark of <0.01 used in this analysis.

role in SLNB decisions.

### Methods

- from 22 centers.
- subsequent visit.
- baseline rates using the Exact binomial test.<sup>6</sup> selection on a logistic regression model

### References

## **Acknowledgments & Disclosures**

**>**CNB, KA, CJ, BM, and SJK are employees and shareholders/option holders of Castle Biosciences, Inc. >JMG is on the speakers bureau at Castle Biosciences. MY has no conflicts to disclose.





<b>Decision Factor</b>	Odds Ratio (95% Cl)
31-GEP	14.8 (6.1-46.8)*
atient preference	32.7 (11.5-126.5)*
infiltrating lymphocytes	4.7 (1.1-22.5)
Breslow thickness	2.6 (1.2-6.2)
Age	2.1 (0.9-5.1)

## Conclusions

The 31-GEP result and patient preference play a significant

>85% of SLNB decisions were influenced by the 31-GEP result. 83% of SLNB decisions that were discordant with 31-GEP results were due to patient preference.

Using the 31-GEP Class 1A result in conjunction with current guidelines resulted in a 29% decrease in SLNBs compared to not using the 31-GEP to help guide SLNB decisions.

Prospectively enrolled patients (n=191) with T1a tumors and at least one high-risk feature, T1b, or T2 tumors were seen by surgical oncologists (89.1%), dermatologists (7.8%), and medical oncologists (3.1%)

Clinicians received 31-GEP results prior to SLNB decisions and were asked which features influenced their decision whether to perform an SLNB. If the procedure was performed, outcomes were recorded at a

**)**To test the impact of the 31-GEP on SLNB rates, in-study procedure rates were compared to varying

The association between clinicopathological features with SLNB performance was studied using stepwise

1. Huang, H., et al. Front Oncol 12, 817510 (2022). 2. Agnese et al. Surgery (2003) 3. Moody et al. EJSO 2017. 4. Marchetti et al. JAMA Derm (2021). 5. Vetto, J. T. et al. Future Oncology 15, 1207-1217 (2019). 6. Whitman, E.D., et al. JCO-PO 5, 1466-79 (2021).